# Healthlink Capital

> Healthlink Capital is a VC fund backing Biotechnology, Medical and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Feb 2019
- Lead investor: 0%
- Last updated: Aug 2026

Healthlink Capital is a VC fund focused on Biotechnology and Medical. Healthlink Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Medical | 2 | 50% |
| Health Care | 2 | 50% |
| Genetics | 1 | 25% |
| Therapeutics | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 2 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 50% |
| United Kingdom | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lyndra Therapeutics | Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximizeglobal health impact and lower overall healthcare costs. | $60.9M | Series B | Feb 11, 2019 |  |
| Congenica | Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of geneticdisease for patients.It was founded in 2013 and headquartered in Cambridge, Cambridgeshire. |  | Series B | Apr 27, 2017 |  |
| Lyndra Therapeutics | Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximizeglobal health impact and lower overall healthcare costs. | $23M | Series A | Apr 13, 2017 |  |
| Sapience Therapeutics | Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States. | $22.5M | Series A | Jul 12, 2016 |  |

4 of 4 investments shown.

## Co-investors
- [GF Securities](https://shizune.co/investors/profile/gf-securities) — VC Fund, 2 deals together
- Partners HealthCare — VC Fund, 2 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 2 deals together
- [Quark Venture](https://shizune.co/investors/profile/quark-venture) — VC Fund, 2 deals together
- [Suffolk Equity Partners](https://shizune.co/investors/profile/suffolk-equity-partners) — VC Fund, 2 deals together
- [Yonghua Capital](https://shizune.co/investors/profile/yongyong-investment) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Healthlink Capital invest in?

Healthlink Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Healthlink Capital last invest?

The most recent investment recorded for Healthlink Capital closed in Feb 2019. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co